Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)

BACKGROUND: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL‐17A, has been shown to have significant efficacy and a favourable safety profile in the treatment of moderate‐to‐severe psoriasis and psoriatic arthritis. OBJECTIVE: To assess the efficacy and safety of secuki...

Descripción completa

Detalles Bibliográficos
Autores principales: Bissonnette, R., Luger, T., Thaçi, D., Toth, D., Lacombe, A., Xia, S., Mazur, R., Patekar, M., Charef, P., Milutinovic, M., Leonardi, C., Mrowietz, U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Psoriasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175198/
https://www.ncbi.nlm.nih.gov/pubmed/29444376
http://dx.doi.org/10.1111/jdv.14878

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175198/
https://www.ncbi.nlm.nih.gov/pubmed/29444376
http://dx.doi.org/10.1111/jdv.14878

Ejemplares similares